Welcome to our dedicated page for Nucana SEC filings (Ticker: NCNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NuCana plc (NCNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Capital Market. NuCana files annual reports on Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934, which together give investors detailed insight into its clinical-stage oncology business, financial position, and capital markets activity.
Through these filings, NuCana reports unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and information on equity financings, warrant issuances and cancellations, and at-the-market offering activity. Form 6-K submissions also include press releases on quarterly financial results, clinical data for NUC-7738 and NUC-3373, Nasdaq listing matters, ADS ratio changes, and corporate governance updates such as leadership transitions and board resignations.
For investors analyzing NuCana’s cancer drug development programs, the filings complement press releases by documenting how clinical progress, such as the NuTide:701 and NuTide:303 studies, is reflected in research and development spending, cash resources, and risk disclosures. While NuCana’s filings do not include U.S. domestic forms like 10-K or 10-Q, the Form 20-F and associated 6-K exhibits serve similar roles in outlining key risks, forward-looking statements, and the company’s dependence on external capital to fund operations.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR and can be paired with AI-powered summaries that highlight important sections, such as liquidity discussions, changes in capital structure, and descriptions of clinical milestones. Users can quickly locate specific 6-K reports tied to financial results, Nasdaq compliance updates, patent announcements, or other material events, and review how NuCana describes its ProTide technology, oncology pipeline, and anticipated cash runway within its official regulatory communications.
NuCana plc granted Chief Operating Officer Theresa Margaret Bruce options over 132,600,130 Ordinary Shares. The options carry an exercise price of 0.0004 Pounds Sterling per share, aligning with the nominal value of the Ordinary Shares.
According to the award terms, 50% of the underlying shares vested on April 15, 2026, with the remaining half scheduled to vest in four equal annual installments, contingent on continued service. Following this grant, Bruce holds options over 132,600,130 Ordinary Shares that expire on April 15, 2036.
NuCana plc director Levy Elliott M. filed an initial statement of beneficial ownership. The filing shows direct holdings of 13 Ordinary Shares and American Depositary Shares (ADSs), where each ADS represents 5,000 Ordinary Shares.
He also reports multiple option awards over 23,811,896 and 28,631,517 Ordinary Shares at exercise prices between 0.0004 and 0.004 Pounds Sterling. Some options are already fully vested and expire between June 20, 2035 and January 14, 2036, while others are scheduled to vest in full on June 20, 2026 and January 14, 2027 subject to continued service. The filing records existing holdings rather than new market purchases or sales.
NuCana plc executive David James Harrison, Head of Translational Medicine, filed an initial Form 3 reporting holdings of options over the company’s Ordinary Shares. The filing lists several option grants, including options over 62,499,995 Ordinary Shares with a 0.004 Pounds Sterling exercise price that fully vested on June 20, 2025 and expire on June 20, 2035.
Other grants referenced include options over 1,971,417, 77,520,679 and 64,471,412 Ordinary Shares at a 0.0004 Pounds Sterling exercise price, with vesting completed on June 20, 2025 or January 14, 2026, and new awards vesting 25% on June 20, 2026 and January 14, 2027 with the remainder in three equal annual installments, subject to continued service.
NuCana plc director Mellish Martin C.B. filed an initial Form 3 disclosing his equity interests in the company. He directly holds 7 American Depositary Shares, and each ADS represents 5,000 ordinary shares of NuCana plc. He also directly holds 28 ordinary shares.
The filing lists several option awards over ordinary shares with very low exercise prices in Pounds Sterling. Some of these options have already fully vested and expire between June 20, 2035 and January 14, 2036, while others are scheduled to vest in full on June 20, 2026 and January 14, 2027, conditional on his continued service with the company.
NuCana plc Chief Medical Officer Jeffrey D. Bloss filed a Form 3 reporting his existing ownership in the company. The filing lists multiple option awards over Ordinary Shares with exercise prices between 0.0004 and 0.004 Pounds Sterling, including grants that are fully vested and others that vest between June 2026 and January 2027, subject to continued service. Bloss also reports direct ownership of 47,136 Ordinary Shares.
NuCana plc reports its 2025 annual results and outlines key risks around its oncology pipeline and funding. The company recorded net losses of £19.0 million in 2024 and £29.4 million in 2025, bringing its accumulated deficit to £252.3 million as of December 31, 2025.
Cash and cash equivalents were £24.3 million at year-end, which management believes will fund operations for at least twelve months, though substantial additional financing will be needed longer term and going-concern risk is highlighted. NuCana’s lead candidates are NUC‑7738, in a Phase 1/2 trial for advanced solid tumors and PD‑1 inhibitor‑resistant melanoma, and NUC‑3373, recently evaluated in a Phase 1b/2 trial in combination regimens. The report emphasizes extensive development, regulatory, funding, market, operational and macroeconomic risks, and notes 20,809,854,947 ordinary shares outstanding as of December 31, 2025.
NuCana plc reported fourth quarter and full-year 2025 results and updated progress on its oncology pipeline. The company recorded a net loss of £2.5 million for Q4 2025 and £29.4 million for the year.
Cash and cash equivalents were £24.3 million as of December 31, 2025, helped by a May 2025 financing that raised £9.6 million in gross proceeds and a July 2025 at-the-market raise of £19.0 million. Management expects existing cash resources to fund planned operations into 2029.
Lead candidate NUC-7738 showed clinical activity and a favorable safety profile in PD‑1 inhibitor‑resistant metastatic melanoma, with partial responses and durable stable disease reported. NuCana plans to complete enrollment in the Phase 2 NuTide:701 expansion study in the first half of 2026 and seek FDA guidance on a potential registrational pathway.
NuCana plc Chief Executive Officer Hugh S. Griffith filed a Schedule 13D reporting beneficial ownership of 2,829,961,890 ordinary shares, equal to 12.0% of NuCana’s 20,809,854,947 ordinary shares outstanding as of March 18, 2026.
The holding includes 1,000,000 ordinary shares, 265,026 ordinary shares in the form of ADSs, and vested options to purchase 2,828,696,864 ordinary shares granted under the company’s equity plans. Griffith states the securities were acquired for investment, with no current plans for corporate actions described in Item 4, though he may change his intentions.
The filing notes it was submitted after the Section 13(d) deadline, attributing the delay to inadvertent administrative oversight and Griffith’s surgery and treatment for serious illness, and states he did not seek or believe he obtained any advantage from the late submission.
NuCana plc filed an initial statement of beneficial ownership for officer Ian Alexander Webster, outlining multiple option grants over its Ordinary Shares. These options carry exercise prices of 0.004 Pounds Sterling or 0.0004 Pounds Sterling, with varying vesting and expiration schedules.
Some option grants over Ordinary Shares completed vesting on June 20, 2025 and January 14, 2026, and expire on June 20, 2035 and January 14, 2036, respectively. Other grants begin vesting 25% on June 20, 2026 and January 14, 2027, with the remainder vesting in three equal annual installments, subject to continued service. The filing reports holdings only, with no buy or sell transactions.
NuCana plc director Kay Andrew Martin has filed an initial Form 3 disclosing significant option holdings over the company’s ordinary shares. The filing reports multiple option awards that together are exercisable into up to 63,648,062 and 52,934,010 Ordinary Shares at very low exercise prices.
According to the footnotes, some options have exercise prices between 0.0004 and 0.004 Pounds Sterling per Ordinary Share, with portions that completed vesting on June 20, 2025 and January 14, 2026 and expirations on June 20, 2035 and January 14, 2036. Other grants will vest in full on June 20, 2026 and January 14, 2027, subject to Martin’s continued service with NuCana through those vesting dates.